Résumé
Metabolic changes contribute to cancer initiation and progression through effects on cancer cells, the tumor microenvironment and whole-body metabolism. Alterations in serine metabolism and the control of one-carbon cycles have emerged as critical for the development of many tumor types. In this Review, we focus on the mitochondrial folate cycle. We discuss recent evidence that, in addition to supporting nucleotide synthesis, mitochondrial folate metabolism also contributes to metastasis through support of antioxidant defense, mitochondrial protein synthesis and the overflow of excess formate. These observations offer potential therapeutic opportunities, including the modulation of formate metabolism through dietary interventions and the use of circulating folate cycle metabolites as biomarkers for cancer detection.
| langue originale | Anglais |
|---|---|
| Pages (de - à) | 701-715 |
| Nombre de pages | 15 |
| journal | Nature Cancer |
| Volume | 5 |
| Numéro de publication | 5 |
| Les DOIs | |
| Etat de la publication | Publié - 2 mai 2024 |
Financement
The work was funded by Cancer Research UK grant C596/A26855 and ERC-2020-ADG PancObese 101020641 and supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CC2073), the UK Medical Research Council (CC2073) and the Wellcome Trust (CC2073). K.H.V. is on the board of directors, is a shareholder of Bristol Myers Squibb and is on the science advisory board (with stock options) of PMV Pharma, Raze Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the SAB of Ludwig Cancer and is a cofounder and consultant (with stock options) of Faeth Therapeutics. She has received research funding from Astex Pharmaceuticals and AstraZeneca and has contributed to CRUK Cancer Research Technology filing patent application WO/2017/144877. The other authors declare no conflicts of interest.
| Bailleurs de fonds | Numéro du bailleur de fonds |
|---|---|
| Medical Research Council | |
| Astex pharmaceuticals | |
| Wellcome Trust | |
| AstraZeneca NV | |
| Horizon 2020 Framework Programme | 101020641 |
| Cancer Research UK | C596/A26855, WO/2017/144877, ERC-2020-ADG PancObese 101020641 |
| Francis Crick Institute | CC2073 |
SDG des Nations Unies
Ce résultat contribue à ou aux Objectifs de développement durable suivants
-
SDG 3 Bonne santé et bien-être
Empreinte digitale
Examiner les sujets de recherche de « Cycling back to folate metabolism in cancer ». Ensemble, ils forment une empreinte digitale unique.Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver